The Hepatitis C antibody screening test (anti-HCV test) is the first-line serological assay for identifying individuals exposed to the hepatitis C virus, playing a critical role in global HCV elimination programs. This article provides a comprehensive technical overview of anti-HCV screening, covering sample types, testing principles, immunoassay platforms, clinical applications, and answers to frequently asked questions.
Technical Overview
The Hepatitis C antibody screening test is a serological assay designed to detect antibodies against the hepatitis C virus (anti-HCV) in human blood. These antibodies, predominantly of the IgG class, are produced by the host immune system in response to HCV infection and generally become detectable approximately 4 to 10 weeks after exposure, with more than 97% of infected individuals seroconverting within 6 months. Because anti-HCV persists for life, a reactive screening result indicates prior exposure to the virus but cannot distinguish between active (current) infection and a resolved past infection.
Modern anti-HCV screening assays utilize recombinant and synthetic peptide antigens derived from immunodominant regions of the HCV genome, including the core, NS3, NS4, and NS5 proteins. Third-generation assays incorporate antigens from the core and NS3 regions to improve sensitivity during the early seroconversion window. Screening is recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) as the initial diagnostic step for all adults aged 18 and older, pregnant women, and individuals with recognized risk factors, in alignment with global HCV elimination targets.
- Target analyte: Total anti-HCV antibodies (predominantly IgG)
- Typical seroconversion window: 4 to 10 weeks post-exposure (may extend to 6 months)
- Indicative sensitivity of third-generation assays: greater than 99% in established infection
- Indicative specificity: approximately 99% in low-prevalence populations
- Reactive screening results require confirmation with HCV RNA nucleic acid testing (NAT)
Testing Samples
Serum
Serum is the preferred and most widely used sample matrix for anti-HCV screening. Venous blood is collected into a plain tube or serum separator tube, allowed to clot for 20 to 30 minutes, and centrifuged to obtain clear serum. Hemolyzed, lipemic, or icteric samples may interfere with optical detection in enzyme immunoassays and should be avoided or noted during interpretation. Serum samples are stable at 2 to 8 degrees Celsius for up to 7 days; for longer storage, freezing at minus 20 degrees Celsius or below is recommended, with avoidance of repeated freeze-thaw cycles.
Plasma
Plasma collected in tubes containing EDTA, citrate, or heparin anticoagulants is acceptable for most chemiluminescent microparticle immunoassay platforms. Plasma is the standard matrix in blood bank donor screening, where HCV antibody and NAT testing are performed in parallel. Highly hemolyzed specimens or those with visible fibrin clots should be re-collected, as they may cause instrument pipetting errors or signal interference.
Dried Blood Spots and Fingerstick Capillary Blood
Dried blood spot (DBS) samples and whole blood collected via fingerstick are increasingly used in resource-limited settings, community outreach programs, and point-of-care testing. Rapid diagnostic tests based on immunochromatographic or immunofiltration principles accept small volumes of capillary blood and can deliver results in 10 to 20 minutes. DBS specimens offer logistical advantages for transport without a cold chain, although slightly reduced analytical sensitivity compared with venous serum should be considered when interpreting negative results.
Testing Items
The primary testing item is the qualitative detection of total antibodies to the hepatitis C virus (anti-HCV). The assay reports results as reactive (positive), non-reactive (negative), or indeterminate based on the signal measured against a validated cutoff value. Supplemental and follow-up items that are commonly ordered alongside or after anti-HCV screening include:
- Anti-HCV screening test (qualitative): initial serological marker of HCV exposure
- Signal-to-cutoff (S/CO) ratio evaluation: used by some laboratories to predict true positivity and guide the need for supplemental testing
- HCV RNA quantitative or qualitative nucleic acid test (NAT): confirms current infection by detecting viral RNA
- HCV core antigen assay: an alternative lower-cost marker of active viremia where NAT is unavailable
- HCV genotyping: performed prior to treatment initiation in certain clinical settings
- Liver function panel (ALT, AST): assessed to evaluate hepatic injury in individuals with confirmed infection
Testing Methods
Enzyme-Linked Immunosorbent Assay (ELISA / EIA)
Third-generation ELISA is the classical screening method. Recombinant HCV antigens (core, NS3, NS4, NS5) are coated onto microplate wells. Patient antibodies bind to the immobilized antigens, and binding is detected using an enzyme-labeled anti-human IgG conjugate and a colorimetric substrate. Absorbance is read spectrophotometrically at 450 nm, and results are interpreted against a calculated cutoff value. ELISA offers high throughput, low reagent cost, and suitability for large-scale epidemiological screening, with a total assay time of approximately 60 to 90 minutes.
Chemiluminescence Immunoassay (CLIA) and Chemiluminescent Microparticle Immunoassay (CMIA)
Automated CLIA and CMIA platforms represent the current mainstream in clinical laboratories. These assays use magnetic microparticles or paramagnetic beads coated with HCV antigens and acridinium- or alkaline-phosphatase-based chemiluminescent detection systems. They provide improved analytical sensitivity, shorter incubation times, higher precision, and full automation. Results are expressed as relative light units (RLU) or signal-to-cutoff (S/CO) ratios, enabling laboratories to apply S/CO thresholds that predict supplemental testing requirements, thereby reducing unnecessary confirmatory testing.
Rapid Diagnostic Tests (RDTs) and Point-of-Care Assays
Immunochromatographic and immunofiltration (flow-through) rapid tests employ colloidal gold or dye-labeled HCV antigens on nitrocellulose strips. A visible test line indicates the presence of anti-HCV in the applied sample. RDTs require no laboratory infrastructure, use fingerstick whole blood, and produce results in 15 to 20 minutes. WHO prequalified rapid tests demonstrate sensitivity above 98% and specificity above 99% compared with laboratory immunoassays, making them valuable for outreach, harm reduction programs, and settings linking screening directly to confirmatory care.
Supplemental Testing Strategy
Following a reactive anti-HCV screening result, current guidelines no longer recommend recombinant immunoblot assay (RIBA), which has been discontinued in favor of direct viral detection. A reactive screen must be followed by HCV RNA NAT to distinguish active infection from a resolved past infection. Individuals who are anti-HCV reactive and RNA negative after 3 to 6 months are considered to have cleared the infection, whereas RNA-positive individuals require linkage to direct-acting antiviral (DAA) therapy.
Applications
Hepatitis C antibody screening is deployed across a broad spectrum of clinical and public health contexts:
- Blood, organ, and tissue donor screening to prevent transfusion- and transplant-associated transmission
- Universal one-time screening of all adults, as recommended by CDC and WHO, and screening of pregnant individuals during each pregnancy
- Targeted screening of high-risk populations, including people who inject drugs, persons with HIV, hemodialysis patients, incarcerated individuals, and those with elevated ALT of unknown cause
- Post-exposure monitoring following occupational needlestick or percutaneous exposure to HCV-positive blood
- Children born to HCV-infected mothers, tested no earlier than 18 months of age to avoid false results from passively transferred maternal antibodies
- Pre-operative and pre-treatment screening, including evaluation prior to immunosuppressive or hepatotoxic therapy
- Epidemiological surveillance and population-based seroprevalence studies supporting national elimination programs
- Confirmation of sustained virologic response follow-up documentation, in which anti-HCV persists and is not used to assess cure
FAQ
What does a reactive (positive) anti-HCV result mean?
A reactive result indicates that the person has been infected with HCV at some point and has developed antibodies. It does not by itself confirm current infection, because antibodies persist even after spontaneous clearance or cure. HCV RNA testing is required to determine whether the infection is active.
What does a non-reactive (negative) result mean?
A non-reactive result means no HCV antibodies were detected. In most cases, this indicates the person has never been infected. However, if exposure occurred within the past 4 to 10 weeks, the person may still be in the window period, and repeat testing or direct HCV RNA testing should be considered.
Can anti-HCV screening be used in infants born to infected mothers?
Maternal IgG antibodies cross the placenta and can persist in infants for up to 18 months, causing false-reactive results. Antibody testing in this population should be deferred until after 18 months of age, with HCV RNA testing used for earlier evaluation when clinically indicated.
Can anti-HCV testing determine whether treatment was successful?
No. Antibodies remain detectable for life regardless of treatment outcome. Cure is confirmed by undetectable HCV RNA at 12 weeks or more after completion of therapy, a result known as sustained virologic response.
How reliable are rapid point-of-care anti-HCV tests?
WHO-prequalified rapid tests achieve sensitivity above 98% and specificity above 99% relative to laboratory immunoassays. Reactive results from any screening platform should still be confirmed with HCV RNA NAT before treatment decisions are made.
What causes false-reactive results?
False-reactive results may occur in autoimmune diseases, hemodialysis patients, recent vaccinations, paraproteinemias, or technical errors. Laboratories reduce this risk by applying validated S/CO ratio thresholds and repeating initially reactive samples before reporting, followed by NAT confirmation.
